+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Nuclear Radiopharmaceutical Market - Global Forecast 2026-2032- Product Image
Nuclear Radiopharmaceutical Market - Global Forecast 2026-2032- Product Image
Sale

Nuclear Radiopharmaceutical Market - Global Forecast 2026-2032

  • Report

  • 184 Pages
  • September 2026
  • Region: Global
  • 360iResearch™
  • ID: 6127401
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Nuclear Radiopharmaceutical Market is projected to reach USD 6.90 Billion in 2026. It is expected to continue growing at a CAGR of 8.37%, reaching USD 11.30 Billion by 2032.

Nuclear Radiopharmaceuticals: Executive Overview

Nuclear radiopharmaceuticals combine a radioactive isotope with a targeting molecule for diagnostic imaging or targeted therapy. Their development is shaped by clinical need, isotope availability, regulatory controls, specialized manufacturing, radiation safety, and the ability to deliver products within short-use windows. The field is progressing from predominantly diagnostic applications toward integrated diagnostic-and-therapeutic pathways, while access remains dependent on infrastructure, trained personnel, and reliable distribution.

From Diagnostic Imaging to Precision Theranostics

The landscape is shifting toward theranostics, in which molecular imaging identifies suitable biology and a related radioligand therapy supports personalized treatment. This transition increases the importance of biomarker selection, companion imaging, dosimetry, patient monitoring, and coordinated care. It also places greater pressure on isotope production, radiochemistry capacity, quality systems, and logistics capable of managing radioactive materials safely and on time.

Artificial Intelligence Strengthens Imaging and Treatment Decisions

Artificial intelligence is being applied to image reconstruction, lesion detection, segmentation, quantification, workflow prioritization, and treatment-response assessment. In radiopharmaceutical development, it can support target identification, molecular design, patient selection, and dosimetry analysis. Responsible adoption requires representative validation datasets, transparent performance evaluation, clinician oversight, cybersecurity, and controls against bias or clinically unsafe automation.

Regional Insights Across the Radiopharmaceutical Ecosystem

North America combines advanced nuclear medicine services, research capacity, and established regulatory pathways, while Latin America is expanding unevenly as access to isotope supply, cyclotrons, imaging equipment, and specialist training varies by country. Europe benefits from strong academic networks and coordinated scientific capabilities, but cross-border distribution and differing national reimbursement processes remain important considerations. The Middle East is investing in specialized healthcare infrastructure, whereas Africa faces wider constraints in equipment, isotope access, and workforce availability. Asia-Pacific presents substantial clinical and manufacturing capabilities alongside significant variation in regulation, infrastructure, and access between mature and emerging healthcare systems.

Group Insights: Cooperation Shapes Access and Capability

ASEAN’s diversity makes regional coordination, shared training, and dependable supply arrangements especially relevant. BRICS members bring substantial scientific, industrial, and healthcare capabilities, but differ markedly in regulatory maturity and access. The European Union benefits from collaborative research and cross-border expertise while managing national differences in healthcare implementation. G7 economies generally have strong research, manufacturing, and clinical infrastructure. GCC countries are developing advanced medical facilities and specialized services, and NATO members can draw on extensive scientific, health-security, and regulatory cooperation, although participation and capability vary across the group.

Country Insights: Diverse National Priorities and Readiness

Australia supports nuclear medicine through research institutions and specialized clinical services; Brazil and Mexico are focused on extending access amid infrastructure and distribution challenges. Canada and the United States have broad clinical and research capabilities, with attention to isotope security and supply resilience. China and India are strengthening domestic production, clinical capacity, and scientific ecosystems. Japan and South Korea maintain sophisticated imaging and manufacturing capabilities. France, Germany, Italy, Spain, and the United Kingdom combine established nuclear medicine expertise with differing reimbursement, procurement, and regulatory environments. Russia retains nuclear science and isotope capabilities, while access to international collaboration and supply channels is an important consideration.

Priorities for Building a Resilient Radiopharmaceutical Ecosystem

Industry leaders should diversify isotope and component sourcing, establish validated contingency logistics, and align manufacturing capacity with clinical delivery windows. They should integrate diagnostic and therapeutic development plans, invest in dosimetry and evidence generation, and engage regulators and healthcare providers early. Partnerships with hospitals, academic centers, and infrastructure operators can expand specialist training and standardized workflows. Organizations should also deploy artificial intelligence through governed validation programs, strengthen radiation-safety systems, and use access-oriented planning to address infrastructure and reimbursement differences across regions.

Methodology: Evidence-Based Executive Synthesis

This executive summary uses a structured qualitative assessment of the nuclear radiopharmaceutical field, organized around technology evolution, clinical adoption, isotope and manufacturing requirements, regulation, infrastructure, artificial intelligence, and geographic readiness. Regional, group, and country observations are synthesized from established characteristics of healthcare systems, nuclear medicine capacity, research ecosystems, logistics, and policy environments. The assessment avoids market estimates, market shares, forecasts, and company-specific claims, and treats differences within each geography or group as material rather than assuming uniform conditions.

Conclusion: Capability, Coordination, and Access Will Define Progress

Nuclear radiopharmaceuticals are moving toward more precise, integrated care pathways, with theranostics and artificial intelligence adding clinical and operational sophistication. Progress will depend not only on scientific advances but also on dependable isotope production, compliant manufacturing, specialist capacity, safe logistics, validated evidence, and workable reimbursement. Leaders that coordinate these elements across institutions and borders will be better positioned to translate innovation into consistent patient access.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. New Revenue Opportunities
3.4. Next-Generation Business Models
3.5. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Nuclear Radiopharmaceutical Market, by Type
7.1. Introduction
7.2. Diagnostic
7.3. Therapeutic
8. Nuclear Radiopharmaceutical Market, by Technology
8.1. Introduction
8.2. Pet
8.3. Spect
9. Nuclear Radiopharmaceutical Market, by Radiotracer
9.1. Introduction
9.2. F-18
9.3. I-131
9.4. Lu-177
9.5. Tc-99M
10. Nuclear Radiopharmaceutical Market, by End User
10.1. Introduction
10.2. Hospitals
10.3. Imaging Centers
10.4. Research Institutes
11. Nuclear Radiopharmaceutical Market, by Application
11.1. Introduction
11.2. Cardiovascular
11.3. Neurology
11.4. Oncology
12. Nuclear Radiopharmaceutical Market, by Region
12.1. Introduction
12.2. Asia-Pacific
12.3. North America
12.4. Latin America
12.5. Europe
12.6. Middle East
12.7. Africa
13. Nuclear Radiopharmaceutical Market, by Group
13.1. Introduction
13.2. ASEAN
13.3. GCC
13.4. European Union
13.5. BRICS
13.6. G7
13.7. NATO
14. Nuclear Radiopharmaceutical Market, by Country
14.1. Introduction
14.2. United States
14.3. Canada
14.4. Mexico
14.5. Brazil
14.6. United Kingdom
14.7. Germany
14.8. France
14.9. Russia
14.10. Italy
14.11. Spain
14.12. China
14.13. India
14.14. Japan
14.15. Australia
14.16. South Korea
15. Competitive Landscape
15.1. Market Share Analysis, 2025
15.2. Market Concentration Analysis, 2025
15.2.1. Concentration Ratio (CR)
15.2.2. Herfindahl Hirschman Index (HHI)
15.3. Recent Developments & Impact Analysis, 2025
15.4. Product Portfolio Analysis, 2025
15.5. Benchmarking Analysis, 2025
16. Company Profiles
16.1. Advanced Accelerator Applications S.A.
16.2. Bayer AG
16.3. Bracco Imaging S.p.A.
16.4. BWXT Medical Ltd.
16.5. Cardinal Health, Inc.
16.6. Clarity Pharmaceuticals Ltd.
16.7. Curium Pharma SAS
16.8. Eckert & Ziegler SE
16.9. Eli Lilly and Company
16.10. GE HealthCare Technologies Inc.
16.11. ITM Isotope Technologies Munich SE
16.12. Jubilant Pharmova Limited
16.13. Lantheus Holdings, Inc.
16.14. NorthStar Medical Radioisotopes, LLC
16.15. Novartis AG
16.16. RayzeBio, Inc.
16.17. Shanghai United Imaging Healthcare Co., Ltd.
16.18. Siemens Healthineers AG
16.19. SOFIE Biosciences, Inc.
16.20. Telix Pharmaceuticals Limited
17. Key Experts
LIST OF FIGURES
FIGURE 1. Global Nuclear Radiopharmaceutical Market, Years Considered for the Study
FIGURE 2. Global Nuclear Radiopharmaceutical Market, Research Design
FIGURE 3. Global Nuclear Radiopharmaceutical Market, Research Framework
FIGURE 4. Global Nuclear Radiopharmaceutical Market, Data Triangulation
FIGURE 5. Global Nuclear Radiopharmaceutical Market Size, 2017-2032 (USD Million)
FIGURE 6. Global Nuclear Radiopharmaceutical Market Size, by Type, 2025 vs 2032 (%)
FIGURE 7. Global Nuclear Radiopharmaceutical Market Size, by Type, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 8. Global Nuclear Radiopharmaceutical Market Size, by Technology, 2025 vs 2032 (%)
FIGURE 9. Global Nuclear Radiopharmaceutical Market Size, by Technology, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 10. Global Nuclear Radiopharmaceutical Market Size, by Radiotracer, 2025 vs 2032 (%)
FIGURE 11. Global Nuclear Radiopharmaceutical Market Size, by Radiotracer, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 12. Global Nuclear Radiopharmaceutical Market Size, by End User, 2025 vs 2032 (%)
FIGURE 13. Global Nuclear Radiopharmaceutical Market Size, by End User, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 14. Global Nuclear Radiopharmaceutical Market Size, by Application, 2025 vs 2032 (%)
FIGURE 15. Global Nuclear Radiopharmaceutical Market Size, by Application, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 16. Global Nuclear Radiopharmaceutical Market Size, by Region, 2025 vs 2032 (%)
FIGURE 17. Global Nuclear Radiopharmaceutical Market Size, by Region, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 18. Global Nuclear Radiopharmaceutical Market Size, by Group, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 19. Global Nuclear Radiopharmaceutical Market Size, by Country, 2025 vs 2032 (%)
FIGURE 20. Global Nuclear Radiopharmaceutical Market Size, by Country, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 21. Global Nuclear Radiopharmaceutical Market Share, by Key Player, 2025
LIST OF TABLES
TABLE 1. Global Nuclear Radiopharmaceutical Market Segmentation & Coverage
TABLE 2. Global Nuclear Radiopharmaceutical Market Size, 2017-2032 (USD Million)
TABLE 3. Global Nuclear Radiopharmaceutical Market Size, by Type, 2017-2032 (USD Million)
TABLE 4. Global Diagnostic Market Size, by Region, 2017-2032 (USD Million)
TABLE 5. Global Diagnostic Market Size, by Group, 2017-2032 (USD Million)
TABLE 6. Global Diagnostic Market Size, by Country, 2017-2032 (USD Million)
TABLE 7. Global Therapeutic Market Size, by Region, 2017-2032 (USD Million)
TABLE 8. Global Therapeutic Market Size, by Group, 2017-2032 (USD Million)
TABLE 9. Global Therapeutic Market Size, by Country, 2017-2032 (USD Million)
TABLE 10. Global Nuclear Radiopharmaceutical Market Size, by Technology, 2017-2032 (USD Million)
TABLE 11. Global Pet Market Size, by Region, 2017-2032 (USD Million)
TABLE 12. Global Pet Market Size, by Group, 2017-2032 (USD Million)
TABLE 13. Global Pet Market Size, by Country, 2017-2032 (USD Million)
TABLE 14. Global Spect Market Size, by Region, 2017-2032 (USD Million)
TABLE 15. Global Spect Market Size, by Group, 2017-2032 (USD Million)
TABLE 16. Global Spect Market Size, by Country, 2017-2032 (USD Million)
TABLE 17. Global Nuclear Radiopharmaceutical Market Size, by Radiotracer, 2017-2032 (USD Million)
TABLE 18. Global F-18 Market Size, by Region, 2017-2032 (USD Million)
TABLE 19. Global F-18 Market Size, by Group, 2017-2032 (USD Million)
TABLE 20. Global F-18 Market Size, by Country, 2017-2032 (USD Million)
TABLE 21. Global I-131 Market Size, by Region, 2017-2032 (USD Million)
TABLE 22. Global I-131 Market Size, by Group, 2017-2032 (USD Million)
TABLE 23. Global I-131 Market Size, by Country, 2017-2032 (USD Million)
TABLE 24. Global Lu-177 Market Size, by Region, 2017-2032 (USD Million)
TABLE 25. Global Lu-177 Market Size, by Group, 2017-2032 (USD Million)
TABLE 26. Global Lu-177 Market Size, by Country, 2017-2032 (USD Million)
TABLE 27. Global Tc-99M Market Size, by Region, 2017-2032 (USD Million)
TABLE 28. Global Tc-99M Market Size, by Group, 2017-2032 (USD Million)
TABLE 29. Global Tc-99M Market Size, by Country, 2017-2032 (USD Million)
TABLE 30. Global Nuclear Radiopharmaceutical Market Size, by End User, 2017-2032 (USD Million)
TABLE 31. Global Hospitals Market Size, by Region, 2017-2032 (USD Million)
TABLE 32. Global Hospitals Market Size, by Group, 2017-2032 (USD Million)
TABLE 33. Global Hospitals Market Size, by Country, 2017-2032 (USD Million)
TABLE 34. Global Imaging Centers Market Size, by Region, 2017-2032 (USD Million)
TABLE 35. Global Imaging Centers Market Size, by Group, 2017-2032 (USD Million)
TABLE 36. Global Imaging Centers Market Size, by Country, 2017-2032 (USD Million)
TABLE 37. Global Research Institutes Market Size, by Region, 2017-2032 (USD Million)
TABLE 38. Global Research Institutes Market Size, by Group, 2017-2032 (USD Million)
TABLE 39. Global Research Institutes Market Size, by Country, 2017-2032 (USD Million)
TABLE 40. Global Nuclear Radiopharmaceutical Market Size, by Application, 2017-2032 (USD Million)
TABLE 41. Global Cardiovascular Market Size, by Region, 2017-2032 (USD Million)
TABLE 42. Global Cardiovascular Market Size, by Group, 2017-2032 (USD Million)
TABLE 43. Global Cardiovascular Market Size, by Country, 2017-2032 (USD Million)
TABLE 44. Global Neurology Market Size, by Region, 2017-2032 (USD Million)
TABLE 45. Global Neurology Market Size, by Group, 2017-2032 (USD Million)
TABLE 46. Global Neurology Market Size, by Country, 2017-2032 (USD Million)
TABLE 47. Global Oncology Market Size, by Region, 2017-2032 (USD Million)
TABLE 48. Global Oncology Market Size, by Group, 2017-2032 (USD Million)
TABLE 49. Global Oncology Market Size, by Country, 2017-2032 (USD Million)
TABLE 50. Global Nuclear Radiopharmaceutical Market Size, by Region, 2017-2032 (USD Million)
TABLE 51. Asia-Pacific Nuclear Radiopharmaceutical Market Size, by Region, 2017-2032 (USD Million)
TABLE 52. Asia-Pacific Nuclear Radiopharmaceutical Market Size, by Type, 2017-2032 (USD Million)
TABLE 53. Asia-Pacific Nuclear Radiopharmaceutical Market Size, by Technology, 2017-2032 (USD Million)
TABLE 54. Asia-Pacific Nuclear Radiopharmaceutical Market Size, by Radiotracer, 2017-2032 (USD Million)
TABLE 55. Asia-Pacific Nuclear Radiopharmaceutical Market Size, by End User, 2017-2032 (USD Million)
TABLE 56. Asia-Pacific Nuclear Radiopharmaceutical Market Size, by Application, 2017-2032 (USD Million)
TABLE 57. North America Nuclear Radiopharmaceutical Market Size, by Region, 2017-2032 (USD Million)
TABLE 58. North America Nuclear Radiopharmaceutical Market Size, by Type, 2017-2032 (USD Million)
TABLE 59. North America Nuclear Radiopharmaceutical Market Size, by Technology, 2017-2032 (USD Million)
TABLE 60. North America Nuclear Radiopharmaceutical Market Size, by Radiotracer, 2017-2032 (USD Million)
TABLE 61. North America Nuclear Radiopharmaceutical Market Size, by End User, 2017-2032 (USD Million)
TABLE 62. North America Nuclear Radiopharmaceutical Market Size, by Application, 2017-2032 (USD Million)
TABLE 63. Latin America Nuclear Radiopharmaceutical Market Size, by Region, 2017-2032 (USD Million)
TABLE 64. Latin America Nuclear Radiopharmaceutical Market Size, by Type, 2017-2032 (USD Million)
TABLE 65. Latin America Nuclear Radiopharmaceutical Market Size, by Technology, 2017-2032 (USD Million)
TABLE 66. Latin America Nuclear Radiopharmaceutical Market Size, by Radiotracer, 2017-2032 (USD Million)
TABLE 67. Latin America Nuclear Radiopharmaceutical Market Size, by End User, 2017-2032 (USD Million)
TABLE 68. Latin America Nuclear Radiopharmaceutical Market Size, by Application, 2017-2032 (USD Million)
TABLE 69. Europe Nuclear Radiopharmaceutical Market Size, by Region, 2017-2032 (USD Million)
TABLE 70. Europe Nuclear Radiopharmaceutical Market Size, by Type, 2017-2032 (USD Million)
TABLE 71. Europe Nuclear Radiopharmaceutical Market Size, by Technology, 2017-2032 (USD Million)
TABLE 72. Europe Nuclear Radiopharmaceutical Market Size, by Radiotracer, 2017-2032 (USD Million)
TABLE 73. Europe Nuclear Radiopharmaceutical Market Size, by End User, 2017-2032 (USD Million)
TABLE 74. Europe Nuclear Radiopharmaceutical Market Size, by Application, 2017-2032 (USD Million)
TABLE 75. Middle East Nuclear Radiopharmaceutical Market Size, by Region, 2017-2032 (USD Million)
TABLE 76. Middle East Nuclear Radiopharmaceutical Market Size, by Type, 2017-2032 (USD Million)
TABLE 77. Middle East Nuclear Radiopharmaceutical Market Size, by Technology, 2017-2032 (USD Million)
TABLE 78. Middle East Nuclear Radiopharmaceutical Market Size, by Radiotracer, 2017-2032 (USD Million)
TABLE 79. Middle East Nuclear Radiopharmaceutical Market Size, by End User, 2017-2032 (USD Million)
TABLE 80. Middle East Nuclear Radiopharmaceutical Market Size, by Application, 2017-2032 (USD Million)
TABLE 81. Africa Nuclear Radiopharmaceutical Market Size, by Region, 2017-2032 (USD Million)
TABLE 82. Africa Nuclear Radiopharmaceutical Market Size, by Type, 2017-2032 (USD Million)
TABLE 83. Africa Nuclear Radiopharmaceutical Market Size, by Technology, 2017-2032 (USD Million)
TABLE 84. Africa Nuclear Radiopharmaceutical Market Size, by Radiotracer, 2017-2032 (USD Million)
TABLE 85. Africa Nuclear Radiopharmaceutical Market Size, by End User, 2017-2032 (USD Million)
TABLE 86. Africa Nuclear Radiopharmaceutical Market Size, by Application, 2017-2032 (USD Million)
TABLE 87. Global Nuclear Radiopharmaceutical Market Size, by Group, 2017-2032 (USD Million)
TABLE 88. ASEAN Nuclear Radiopharmaceutical Market Size, by Group, 2017-2032 (USD Million)
TABLE 89. ASEAN Nuclear Radiopharmaceutical Market Size, by Type, 2017-2032 (USD Million)
TABLE 90. ASEAN Nuclear Radiopharmaceutical Market Size, by Technology, 2017-2032 (USD Million)
TABLE 91. ASEAN Nuclear Radiopharmaceutical Market Size, by Radiotracer, 2017-2032 (USD Million)
TABLE 92. ASEAN Nuclear Radiopharmaceutical Market Size, by End User, 2017-2032 (USD Million)
TABLE 93. ASEAN Nuclear Radiopharmaceutical Market Size, by Application, 2017-2032 (USD Million)
TABLE 94. GCC Nuclear Radiopharmaceutical Market Size, by Group, 2017-2032 (USD Million)
TABLE 95. GCC Nuclear Radiopharmaceutical Market Size, by Type, 2017-2032 (USD Million)
TABLE 96. GCC Nuclear Radiopharmaceutical Market Size, by Technology, 2017-2032 (USD Million)
TABLE 97. GCC Nuclear Radiopharmaceutical Market Size, by Radiotracer, 2017-2032 (USD Million)
TABLE 98. GCC Nuclear Radiopharmaceutical Market Size, by End User, 2017-2032 (USD Million)
TABLE 99. GCC Nuclear Radiopharmaceutical Market Size, by Application, 2017-2032 (USD Million)
TABLE 100. European Union Nuclear Radiopharmaceutical Market Size, by Group, 2017-2032 (USD Million)
TABLE 101. European Union Nuclear Radiopharmaceutical Market Size, by Type, 2017-2032 (USD Million)
TABLE 102. European Union Nuclear Radiopharmaceutical Market Size, by Technology, 2017-2032 (USD Million)
TABLE 103. European Union Nuclear Radiopharmaceutical Market Size, by Radiotracer, 2017-2032 (USD Million)
TABLE 104. European Union Nuclear Radiopharmaceutical Market Size, by End User, 2017-2032 (USD Million)
TABLE 105. European Union Nuclear Radiopharmaceutical Market Size, by Application, 2017-2032 (USD Million)
TABLE 106. BRICS Nuclear Radiopharmaceutical Market Size, by Group, 2017-2032 (USD Million)
TABLE 107. BRICS Nuclear Radiopharmaceutical Market Size, by Type, 2017-2032 (USD Million)
TABLE 108. BRICS Nuclear Radiopharmaceutical Market Size, by Technology, 2017-2032 (USD Million)
TABLE 109. BRICS Nuclear Radiopharmaceutical Market Size, by Radiotracer, 2017-2032 (USD Million)
TABLE 110. BRICS Nuclear Radiopharmaceutical Market Size, by End User, 2017-2032 (USD Million)
TABLE 111. BRICS Nuclear Radiopharmaceutical Market Size, by Application, 2017-2032 (USD Million)
TABLE 112. G7 Nuclear Radiopharmaceutical Market Size, by Group, 2017-2032 (USD Million)
TABLE 113. G7 Nuclear Radiopharmaceutical Market Size, by Type, 2017-2032 (USD Million)
TABLE 114. G7 Nuclear Radiopharmaceutical Market Size, by Technology, 2017-2032 (USD Million)
TABLE 115. G7 Nuclear Radiopharmaceutical Market Size, by Radiotracer, 2017-2032 (USD Million)
TABLE 116. G7 Nuclear Radiopharmaceutical Market Size, by End User, 2017-2032 (USD Million)
TABLE 117. G7 Nuclear Radiopharmaceutical Market Size, by Application, 2017-2032 (USD Million)
TABLE 118. NATO Nuclear Radiopharmaceutical Market Size, by Group, 2017-2032 (USD Million)
TABLE 119. NATO Nuclear Radiopharmaceutical Market Size, by Type, 2017-2032 (USD Million)
TABLE 120. NATO Nuclear Radiopharmaceutical Market Size, by Technology, 2017-2032 (USD Million)
TABLE 121. NATO Nuclear Radiopharmaceutical Market Size, by Radiotracer, 2017-2032 (USD Million)
TABLE 122. NATO Nuclear Radiopharmaceutical Market Size, by End User, 2017-2032 (USD Million)
TABLE 123. NATO Nuclear Radiopharmaceutical Market Size, by Application, 2017-2032 (USD Million)
TABLE 124. Global Nuclear Radiopharmaceutical Market Size, by Country, 2017-2032 (USD Million)
TABLE 125. United States Nuclear Radiopharmaceutical Market Size, 2017-2032 (USD Million)
TABLE 126. United States Nuclear Radiopharmaceutical Market Size, by Type, 2017-2032 (USD Million)
TABLE 127. United States Nuclear Radiopharmaceutical Market Size, by Technology, 2017-2032 (USD Million)
TABLE 128. United States Nuclear Radiopharmaceutical Market Size, by Radiotracer, 2017-2032 (USD Million)
TABLE 129. United States Nuclear Radiopharmaceutical Market Size, by End User, 2017-2032 (USD Million)
TABLE 130. United States Nuclear Radiopharmaceutical Market Size, by Application, 2017-2032 (USD Million)
TABLE 131. Canada Nuclear Radiopharmaceutical Market Size, 2017-2032 (USD Million)
TABLE 132. Canada Nuclear Radiopharmaceutical Market Size, by Type, 2017-2032 (USD Million)
TABLE 133. Canada Nuclear Radiopharmaceutical Market Size, by Technology, 2017-2032 (USD Million)
TABLE 134. Canada Nuclear Radiopharmaceutical Market Size, by Radiotracer, 2017-2032 (USD Million)
TABLE 135. Canada Nuclear Radiopharmaceutical Market Size, by End User, 2017-2032 (USD Million)
TABLE 136. Canada Nuclear Radiopharmaceutical Market Size, by Application, 2017-2032 (USD Million)
TABLE 137. Mexico Nuclear Radiopharmaceutical Market Size, 2017-2032 (USD Million)
TABLE 138. Mexico Nuclear Radiopharmaceutical Market Size, by Type, 2017-2032 (USD Million)
TABLE 139. Mexico Nuclear Radiopharmaceutical Market Size, by Technology, 2017-2032 (USD Million)
TABLE 140. Mexico Nuclear Radiopharmaceutical Market Size, by Radiotracer, 2017-2032 (USD Million)
TABLE 141. Mexico Nuclear Radiopharmaceutical Market Size, by End User, 2017-2032 (USD Million)
TABLE 142. Mexico Nuclear Radiopharmaceutical Market Size, by Application, 2017-2032 (USD Million)
TABLE 143. Brazil Nuclear Radiopharmaceutical Market Size, 2017-2032 (USD Million)
TABLE 144. Brazil Nuclear Radiopharmaceutical Market Size, by Type, 2017-2032 (USD Million)
TABLE 145. Brazil Nuclear Radiopharmaceutical Market Size, by Technology, 2017-2032 (USD Million)
TABLE 146. Brazil Nuclear Radiopharmaceutical Market Size, by Radiotracer, 2017-2032 (USD Million)
TABLE 147. Brazil Nuclear Radiopharmaceutical Market Size, by End User, 2017-2032 (USD Million)
TABLE 148. Brazil Nuclear Radiopharmaceutical Market Size, by Application, 2017-2032 (USD Million)
TABLE 149. United Kingdom Nuclear Radiopharmaceutical Market Size, 2017-2032 (USD Million)
TABLE 150. United Kingdom Nuclear Radiopharmaceutical Market Size, by Type, 2017-2032 (USD Million)
TABLE 151. United Kingdom Nuclear Radiopharmaceutical Market Size, by Technology, 2017-2032 (USD Million)
TABLE 152. United Kingdom Nuclear Radiopharmaceutical Market Size, by Radiotracer, 2017-2032 (USD Million)
TABLE 153. United Kingdom Nuclear Radiopharmaceutical Market Size, by End User, 2017-2032 (USD Million)
TABLE 154. United Kingdom Nuclear Radiopharmaceutical Market Size, by Application, 2017-2032 (USD Million)
TABLE 155. Germany Nuclear Radiopharmaceutical Market Size, 2017-2032 (USD Million)
TABLE 156. Germany Nuclear Radiopharmaceutical Market Size, by Type, 2017-2032 (USD Million)
TABLE 157. Germany Nuclear Radiopharmaceutical Market Size, by Technology, 2017-2032 (USD Million)
TABLE 158. Germany Nuclear Radiopharmaceutical Market Size, by Radiotracer, 2017-2032 (USD Million)
TABLE 159. Germany Nuclear Radiopharmaceutical Market Size, by End User, 2017-2032 (USD Million)
TABLE 160. Germany Nuclear Radiopharmaceutical Market Size, by Application, 2017-2032 (USD Million)
TABLE 161. France Nuclear Radiopharmaceutical Market Size, 2017-2032 (USD Million)
TABLE 162. France Nuclear Radiopharmaceutical Market Size, by Type, 2017-2032 (USD Million)
TABLE 163. France Nuclear Radiopharmaceutical Market Size, by Technology, 2017-2032 (USD Million)
TABLE 164. France Nuclear Radiopharmaceutical Market Size, by Radiotracer, 2017-2032 (USD Million)
TABLE 165. France Nuclear Radiopharmaceutical Market Size, by End User, 2017-2032 (USD Million)
TABLE 166. France Nuclear Radiopharmaceutical Market Size, by Application, 2017-2032 (USD Million)
TABLE 167. Russia Nuclear Radiopharmaceutical Market Size, 2017-2032 (USD Million)
TABLE 168. Russia Nuclear Radiopharmaceutical Market Size, by Type, 2017-2032 (USD Million)
TABLE 169. Russia Nuclear Radiopharmaceutical Market Size, by Technology, 2017-2032 (USD Million)
TABLE 170. Russia Nuclear Radiopharmaceutical Market Size, by Radiotracer, 2017-2032 (USD Million)
TABLE 171. Russia Nuclear Radiopharmaceutical Market Size, by End User, 2017-2032 (USD Million)
TABLE 172. Russia Nuclear Radiopharmaceutical Market Size, by Application, 2017-2032 (USD Million)
TABLE 173. Italy Nuclear Radiopharmaceutical Market Size, 2017-2032 (USD Million)
TABLE 174. Italy Nuclear Radiopharmaceutical Market Size, by Type, 2017-2032 (USD Million)
TABLE 175. Italy Nuclear Radiopharmaceutical Market Size, by Technology, 2017-2032 (USD Million)
TABLE 176. Italy Nuclear Radiopharmaceutical Market Size, by Radiotracer, 2017-2032 (USD Million)
TABLE 177. Italy Nuclear Radiopharmaceutical Market Size, by End User, 2017-2032 (USD Million)
TABLE 178. Italy Nuclear Radiopharmaceutical Market Size, by Application, 2017-2032 (USD Million)
TABLE 179. Spain Nuclear Radiopharmaceutical Market Size, 2017-2032 (USD Million)
TABLE 180. Spain Nuclear Radiopharmaceutical Market Size, by Type, 2017-2032 (USD Million)
TABLE 181. Spain Nuclear Radiopharmaceutical Market Size, by Technology, 2017-2032 (USD Million)
TABLE 182. Spain Nuclear Radiopharmaceutical Market Size, by Radiotracer, 2017-2032 (USD Million)
TABLE 183. Spain Nuclear Radiopharmaceutical Market Size, by End User, 2017-2032 (USD Million)
TABLE 184. Spain Nuclear Radiopharmaceutical Market Size, by Application, 2017-2032 (USD Million)
TABLE 185. China Nuclear Radiopharmaceutical Market Size, 2017-2032 (USD Million)
TABLE 186. China Nuclear Radiopharmaceutical Market Size, by Type, 2017-2032 (USD Million)
TABLE 187. China Nuclear Radiopharmaceutical Market Size, by Technology, 2017-2032 (USD Million)
TABLE 188. China Nuclear Radiopharmaceutical Market Size, by Radiotracer, 2017-2032 (USD Million)
TABLE 189. China Nuclear Radiopharmaceutical Market Size, by End User, 2017-2032 (USD Million)
TABLE 190. China Nuclear Radiopharmaceutical Market Size, by Application, 2017-2032 (USD Million)
TABLE 191. India Nuclear Radiopharmaceutical Market Size, 2017-2032 (USD Million)
TABLE 192. India Nuclear Radiopharmaceutical Market Size, by Type, 2017-2032 (USD Million)
TABLE 193. India Nuclear Radiopharmaceutical Market Size, by Technology, 2017-2032 (USD Million)
TABLE 194. India Nuclear Radiopharmaceutical Market Size, by Radiotracer, 2017-2032 (USD Million)
TABLE 195. India Nuclear Radiopharmaceutical Market Size, by End User, 2017-2032 (USD Million)
TABLE 196. India Nuclear Radiopharmaceutical Market Size, by Application, 2017-2032 (USD Million)
TABLE 197. Japan Nuclear Radiopharmaceutical Market Size, 2017-2032 (USD Million)
TABLE 198. Japan Nuclear Radiopharmaceutical Market Size, by Type, 2017-2032 (USD Million)
TABLE 199. Japan Nuclear Radiopharmaceutical Market Size, by Technology, 2017-2032 (USD Million)
TABLE 200. Japan Nuclear Radiopharmaceutical Market Size, by Radiotracer, 2017-2032 (USD Million)
TABLE 201. Japan Nuclear Radiopharmaceutical Market Size, by End User, 2017-2032 (USD Million)
TABLE 202. Japan Nuclear Radiopharmaceutical Market Size, by Application, 2017-2032 (USD Million)
TABLE 203. Australia Nuclear Radiopharmaceutical Market Size, 2017-2032 (USD Million)
TABLE 204. Australia Nuclear Radiopharmaceutical Market Size, by Type, 2017-2032 (USD Million)
TABLE 205. Australia Nuclear Radiopharmaceutical Market Size, by Technology, 2017-2032 (USD Million)
TABLE 206. Australia Nuclear Radiopharmaceutical Market Size, by Radiotracer, 2017-2032 (USD Million)
TABLE 207. Australia Nuclear Radiopharmaceutical Market Size, by End User, 2017-2032 (USD Million)
TABLE 208. Australia Nuclear Radiopharmaceutical Market Size, by Application, 2017-2032 (USD Million)
TABLE 209. South Korea Nuclear Radiopharmaceutical Market Size, 2017-2032 (USD Million)
TABLE 210. South Korea Nuclear Radiopharmaceutical Market Size, by Type, 2017-2032 (USD Million)
TABLE 211. South Korea Nuclear Radiopharmaceutical Market Size, by Technology, 2017-2032 (USD Million)
TABLE 212. South Korea Nuclear Radiopharmaceutical Market Size, by Radiotracer, 2017-2032 (USD Million)
TABLE 213. South Korea Nuclear Radiopharmaceutical Market Size, by End User, 2017-2032 (USD Million)
TABLE 214. South Korea Nuclear Radiopharmaceutical Market Size, by Application, 2017-2032 (USD Million)
TABLE 215. Global Nuclear Radiopharmaceutical Market Share, by Key Player, 2025
TABLE 216. Global Nuclear Radiopharmaceutical Market, Key Experts

Companies Mentioned

  • Advanced Accelerator Applications S.A.
  • Bayer AG
  • Bracco Imaging S.p.A.
  • BWXT Medical Ltd.
  • Cardinal Health, Inc.
  • Clarity Pharmaceuticals Ltd.
  • Curium Pharma SAS
  • Eckert & Ziegler SE
  • Eli Lilly and Company
  • GE HealthCare Technologies Inc.
  • ITM Isotope Technologies Munich SE
  • Jubilant Pharmova Limited
  • Lantheus Holdings, Inc.
  • NorthStar Medical Radioisotopes, LLC
  • Novartis AG
  • RayzeBio, Inc.
  • Shanghai United Imaging Healthcare Co., Ltd.
  • Siemens Healthineers AG
  • SOFIE Biosciences, Inc.
  • Telix Pharmaceuticals Limited

Related Topics

Related Reports

Nuclear Medicine & Radiopharmaceuticals Market - Global Forecast 2026-2032 - Product Image

Nuclear Medicine & Radiopharmaceuticals Market - Global Forecast 2026-2032

  • Report
  • 183 Pages
  • Global
From
Radiopharmaceuticals Market - Global Forecast 2026-2032 - Product Image

Radiopharmaceuticals Market - Global Forecast 2026-2032

  • Report
  • 199 Pages
  • Global
From
Nuclear Medicine (Radiopharmaceuticals) - Market Insights, Competitive Landscape, and Market Forecast - 2034 - Product Image

Nuclear Medicine (Radiopharmaceuticals) - Market Insights, Competitive Landscape, and Market Forecast - 2034

  • Report
  • 150 Pages
  • Global
From
Radiopharmaceutical Synthesizer Market Report: Trends, Forecast and Competitive Analysis to 2031 - Product Image

Radiopharmaceutical Synthesizer Market Report: Trends, Forecast and Competitive Analysis to 2031

  • Report
  • 150 Pages
  • Global
From
Radiopharmaceuticals Market Report by Product Type, Application, End Use, and Region 2026-2034 - Product Image

Radiopharmaceuticals Market Report by Product Type, Application, End Use, and Region 2026-2034

  • Report
  • 147 Pages
  • Global
From
Copyright © 2002-2026 Research and Markets. All Rights Reserved.